Axitinib, one of the most potent and latest anti-angiogenic tyrosine kinase inhibitors currently under evaluation for the treatment of NSCLC, is a highly selective inhibitor of VEGFR-1, -2, and -3 [36]. Here, FLT1 is linked to non-small cell lung carcinoma.